Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16998406 | 0.89 | GRM5 (0.39) | GRM5MKNK2CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL19570894 | 0.79 | MKNK2 (0.37) | GRM5MKNK2CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL21944713 | 0.76 | MKNK2 (0.37) | MKNK2CYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL11916077 | 0.73 | CYP3A4 (0.38) | GRM5CYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL8497505 | 0.73 | MAOA (0.42) | CYP3A4CYP2D6CYP1A2CYP2C19MEN1 | |
| SCHEMBL16692778 | 0.73 | CYP3A4 (0.36) | MKNK2CYP3A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL18256099 | 0.72 | CYP3A4 (0.35) | CYP3A4CYP2D6CYP1A2CYP2C19MEN1 | |
| SCHEMBL7923008 | 0.71 | GRM5 (0.54) | GRM5MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL17813500 | 0.71 | GRM5 (0.40) | GRM5APPMAOAMAOBDRD2 | |
| SCHEMBL30953981 | 0.71 | CYP11B2 (0.40) | MKNK2CYP3A4CYP2D6CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2022263548-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | LEAD DISCOVERY CENTER GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4104901-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | Lead Discovery Center GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2021-05-27 | — | — | US | disclosed |
| WO-2021038095-A1 | PEPTIDES AND METHODS FOR THE CARBON-CARBON BOND FORMATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-03-04 | — | — | WO | disclosed |
| EP-3786290-A1 | PEPTIDES AND METHODS FOR THE CARBON-CARBON BOND FORMATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-03-03 | — | — | EP | disclosed |
| US-10633389-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-9738651-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| WO-2017071636-A1 | PHTHALAZINE KETONE DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2017-05-04 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| EP-2210881-A1 | Derivatives of syringolin A | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081731-A2 | DERIVATIVES OF SYRINGOLIN A | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V (DE) | 2010-07-22 | — | — | WO | disclosed |
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | TECHNISCHE UNIVERSITAT DARMSTADT (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | TECHNISCHE UNIVERSITAT DARMSTADT (DE) | 2010-06-17 | — | — | US | disclosed |
| WO-2009068322-A1 | SELECTIVE INHIBITION OF POLO-LIKE KINASE 1 | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENS CHAFTEN E.V. (DE) | 2009-06-04 | — | — | WO | disclosed |
| EP-2065039-A1 | Selective inhibition of Polo-like kinase 1 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008052804-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1918286-A1 | Thiazolhydrazides for treatment of neurodegenerative diseases | MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | GRM5 1510/4885MKNK2 3105/4885CYP3A4 1389/4885 |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | GRM5 1510/4885MKNK2 3105/4885CYP3A4 1389/4885 |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | GRM5 1514/4885MKNK2 3066/4885CYP3A4 1387/4885 |
| US-20100285145-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | GRM5 71/4885MKNK2 2520/4885CYP3A4 2077/4885 |
| US-20100151064-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, MAPT, SNCA | GRM5 682/4885MKNK2 1517/4885CYP3A4 2610/4885 |
| US-10633389-B2 | CARM1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | GRM5 1510/4885MKNK2 3105/4885CYP3A4 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.